PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20877636-0	2010	Additional serine/threonine phosphorylation reduces binding affinity but preserves interface topography of substrate proteins to the c-Cbl TKB domain.	Threonine	18-27	Cbl proto-oncogene	Homo sapiens	133-138	
20877636-8	2010	This obvious reduction in binding affinity, however, indicates that Cbl"s interactions with its TKB-centered binding partners may be more favorable in the absence of Ser/Thr phosphorylation, which is stimulation and context specific in vivo.	Threonine	170-173	Cbl proto-oncogene	Homo sapiens	68-71	
17255109-10	2007	c-Cbl binding likely targets Spry2 for ubiquitin-linked destruction, whereas the phosphatase binding and activity are necessary to dephosphorylate specific Ser/Thr residues.	Threonine	160-163	Cbl proto-oncogene	Homo sapiens	0-5	
18662810-5	2008	CBL showed maximum affinity for human tumor-associated Tn-antigens (GalNAcalpha1-Ser/Thr) at the molecular level and was 3.5 times higher than GalNAc.	Threonine	85-88	Cbl proto-oncogene	Homo sapiens	0-3	
10623852-5	2000	Tyrosine phosphorylation of Cbl in response to CD32 cross-linking was inhibited by calyculin, and this inhibition was linked with a slower electrophoretic mobility of Cbl as a consequence of its phosphorylation on serine/threonine residues.	Threonine	221-230	Cbl proto-oncogene	Homo sapiens	28-31	
10623852-5	2000	Tyrosine phosphorylation of Cbl in response to CD32 cross-linking was inhibited by calyculin, and this inhibition was linked with a slower electrophoretic mobility of Cbl as a consequence of its phosphorylation on serine/threonine residues.	Threonine	221-230	Cbl proto-oncogene	Homo sapiens	167-170